Suven Pharmaceuticals Future Growth
Future criteria checks 2/6
Suven Pharmaceuticals is forecast to grow earnings and revenue by 9.8% and 12.6% per annum respectively. EPS is expected to grow by 11.9% per annum. Return on equity is forecast to be 17.4% in 3 years.
Key information
9.8%
Earnings growth rate
11.9%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 12.6% |
| Future return on equity | 17.4% |
| Analyst coverage | Low |
| Last updated | 19 Apr 2024 |
Recent future growth updates
Recent updates
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Dec 15
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)
Aug 03Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
May 12Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected
Mar 26Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching
Mar 07These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Nov 30Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?
Sep 03Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly
Aug 04Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report
Jun 11With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting
Apr 13Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
Mar 08Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?
Feb 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2026 | 14,800 | 4,410 | N/A | N/A | 1 |
| 3/31/2025 | 13,210 | 3,900 | N/A | N/A | 1 |
| 3/31/2024 | 10,898 | 3,342 | N/A | N/A | 2 |
| 12/31/2023 | 11,678 | 3,709 | N/A | N/A | N/A |
| 9/30/2023 | 13,017 | 4,318 | 3,130 | 4,318 | N/A |
| 6/30/2023 | 13,491 | 4,243 | N/A | N/A | N/A |
| 3/31/2023 | 13,403 | 4,113 | 1,651 | 4,509 | N/A |
| 12/31/2022 | 13,348 | 3,790 | N/A | N/A | N/A |
| 9/30/2022 | 13,726 | 4,313 | 2,522 | 4,787 | N/A |
| 6/30/2022 | 13,952 | 4,563 | N/A | N/A | N/A |
| 3/31/2022 | 13,202 | 4,538 | 2,548 | 3,300 | N/A |
| 12/31/2021 | 12,155 | 4,453 | N/A | N/A | N/A |
| 9/30/2021 | 10,989 | 3,988 | 2,561 | 3,465 | N/A |
| 6/30/2021 | 10,353 | 3,759 | N/A | N/A | N/A |
| 3/31/2021 | 10,097 | 3,623 | 2,717 | 3,825 | N/A |
| 12/31/2020 | 9,353 | 3,534 | N/A | N/A | N/A |
| 9/30/2020 | 8,391 | 2,977 | 2,518 | 3,843 | N/A |
| 6/30/2020 | 8,746 | 3,166 | N/A | N/A | N/A |
| 3/31/2020 | 8,338 | 3,170 | 3,039 | 4,069 | N/A |
| 3/31/2019 | 9,068 | 2,623 | -153 | 1,210 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SUVENPHAR's forecast earnings growth (9.8% per year) is above the savings rate (6.7%).
Earnings vs Market: SUVENPHAR's earnings (9.8% per year) are forecast to grow slower than the Indian market (17.5% per year).
High Growth Earnings: SUVENPHAR's earnings are forecast to grow, but not significantly.
Revenue vs Market: SUVENPHAR's revenue (12.6% per year) is forecast to grow faster than the Indian market (9.9% per year).
High Growth Revenue: SUVENPHAR's revenue (12.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SUVENPHAR's Return on Equity is forecast to be low in 3 years time (17.4%).